Axonics (Nasdaq:AXNX) announced today that it has been granted eight patents and allowed a further four applications in the past 12 months.
Irvine, California-based Axonics eight granted patents and four applications to the U.S. Patent and Trademark Office relate to its portfolio of sacral neuromodulation (SNM) technology.
According to a news release, the patents represent technology internally developed by the company, including the Axonics external trial system, tined lead, implantable neurostimulator, clinician programmer, wireless charging system and patient remote control.
“Axonics is committed to developing best-in-class technology to serve the unmet needs of the millions of adults suffering from incontinence. The volume, subject matter diversity, and breadth of these patents demonstrate the investment in innovation that Axonics continues to make in sacral neuromodulation technology,” said Axoncis CEO Raymond W. Cohen.
The granted U.S. patents are numbered: 11,083,903; 11,110,283; 11,116,985; 11,123,569; 11,213,675; 11,260,236; 11,389,659; and D952,859. The allowed U.S. patent applications are numbered: 16/547,324; 16/871,738; 16/913,532; and 16/882,295.
It’s been a strong 2022 for Axonics, which earlier this month announced that it anticipates full-year revenues of $253 million, rising from the previous guidance of $238 million. That amount of sales would represent a 40% increase from fiscal 2021.
Axonics also filed a premarket approval (PMA) supplement with the FDA for its next-generation neurostimulator in May. The regulatory filing followed the U.S. commercial launch of the Axonics F15 long-lived, recharge-free system in April. The F15 system had received FDA approval in March.